623
Participants
Start Date
May 21, 2013
Primary Completion Date
May 22, 2019
Study Completion Date
May 22, 2019
Octagam 5%
Intravenous immunoglobulin 5%
Other marketed IVIG product
Any intravenous immunoglobulin marketed product approved for the treatment of PID
Octapharma Research Site, New York
Octapharma Research Site, New York
Octapharma Research Site, East Setauket
Octapharma Research Site, Anderson
Octapharma Research Site, Roswell
Octapharma Research Site, Nashville
Octapharma Research Site, Fort Mitchell
Octapharma Research Site, Columbus
Octapharma Research Site, Toledo
Octapharma Research Site, Mayfield Heights
Octapharma Research Site, Fort Wayne
Octapharma Research Site, Farmington Hills
Octapharma Research Site, Plymouth
Octapharma Research Site, Plymouth
Octapharma Research Site, Chicago
Octapharma Research Site, Springfield
Octapharma Research Site, Wichita
Octapharma Research Site, Omaha
Octapharma Research Site, Irving
Octapharma Research Site, Dallas
Octapharma Research Site, Amarillo
Octapharma Research Site, Centennial
Octapharma Research Site, Los Angeles
Octapharma Research Site, Granada Hills
Octapharma Research Site, Redlands
Octapharma Research Site, Irvine
Octapharma Research Site, Pawtucket
Lead Sponsor
Octapharma
INDUSTRY